바이오모아 (BioMoa) — ADC · Antibody

9268프로그램 35FDA 승인

153오늘 방문

1,064누적 방문

8046갱신 대기 S–CData Tier S/A/B차세대 1068HER2 breast 5456Antibody 2744CGT →Psoriasis →NSCLC 35FDA 승인

피드 Data Tier 차세대

최근 활동

RSS →

AntibodystaleRadboud University Medical Cent…Preclinical

111Indium-bevacizumab (111Indium-bevacizumab)

Clear Cell Renal Cell Carcinoma · Clear Cell Renal Cell Carcinoma

#ClearCellRenalCellCarcinoma#Antibody#Preclinical#항체#면역항체+2

임상시험 1상태 ACTIVE

AntibodystaleBeijing Biostar Pharmaceuticals…Phase 2

Utidelone combined with Bevacizumab (Utidelone combined with Bevacizumab)

Non-small Cell Lung Cancer Patients with Brain Metastases · Non-small Cell Lung Cancer Patients with

#Non-smallCellLungCancerPatientsw#Antibody#Phase2#항체#면역항체+2

임상시험 1상태 RECRUITING

AntibodystaleRochePhase 3

Bevacizumab + Pemetrexed (Bevacizumab + Pemetrexed)

Non-squamous Non-small Cell Lung Cancer · Non-squamous Non-small Cell Lung Cancer

#Non-squamousNon-smallCellLungCan#Antibody#Phase3#항체#면역항체+2

임상시험 1상태 ACTIVE

AntibodystaleRochePhase 3

Bevacizumab + Pemetrexed + Carboplatin (Bevacizumab + Pemetrexed + Carboplatin)

Non-squamous Non-small Cell Lung Cancer · Non-squamous Non-small Cell Lung Cancer

#Non-squamousNon-smallCellLungCan#Antibody#Phase3#항체#면역항체+2

임상시험 1상태 ACTIVE

AntibodystaleHunan Province Tumor HospitalPhase 2

IBI-323 combined with bevacizumab plus Platinum (IBI-323 combined with bevacizumab plus Platinum)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase2#항체#면역항체+2

임상시험 1상태 ACTIVE

AntibodystaleWomen's Hospital School Of Medi…Phase 2

PD-1 inhibitor， bevacizumab (PD-1 inhibitor， bevacizumab)

Gestational Trophoblastic Neoplasia · PD-1

#PD-1#Antibody#Phase2#항체#면역항체+3

임상시험 1상태 ACTIVE

AntibodystaleRochePhase 2

bevacizumab and Irinotecan and radiotherapy (bevacizumab and Irinotecan and radiotherapy)

Glioblastoma Multiforme · Glioblastoma Multiforme

#GlioblastomaMultiforme#Antibody#Phase2#항체#면역항체+2

임상시험 1상태 ACTIVE

AntibodystaleGlaxoSmithKlinePreclinical

sunitinib, sorafenib, bevacizumab, and pazopanib (Targeted agents indicated in management of advanced/metastatic RCC, Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib))

Carcinoma, Renal Cell · Carcinoma, Renal Cell

#CarcinomaRenalCell#Antibody#Preclinical#항체#면역항체+4

임상시험 1상태 ACTIVE

AntibodystaleFudan UniversityPhase 2

Faminitib or bevacizumab (Faminitib or bevacizumab)

Pancreatic Cancer · Pancreatic Cancer

#PancreaticCancer#Antibody#Phase2#항체#면역항체+2

임상시험 1상태 RECRUITING

AntibodystaleRochePhase 2

Bevacizumab and Temozolomide and radiotherapy (Bevacizumab and Temozolomide and radiotherapy)

Glioblastoma Multiforme · Glioblastoma Multiforme

#GlioblastomaMultiforme#Antibody#Phase2#항체#면역항체+2

임상시험 1상태 ACTIVE

AntibodyBiologicstaleHenan Provincial People's Hospi…Preclinical

Gene evolution and molecular response under Bevacizumab treatment (Gene evolution and molecular response under Bevacizumab treatment)

Genetic Change · Genetic Change

#GeneticChange#Antibody#Preclinical#항체#면역항체+2

임상시험 1상태 RECRUITING

AntibodystaleAsan Medical CenterApproved

TDM-based infliximab intravenous therapy (TDM-based infliximab intravenous therapy)

Crohn Disease; Infliximab · Crohn Disease

#CrohnDisease#Antibody#Approved#항체#면역항체+3

임상시험 1상태 RECRUITING

AntibodystaleSamsung Bioepis Co., Ltd.Phase 3

proposed biosimilar to infliximab (SB2, SB2 (proposed biosimilar to infliximab))

Rheumatoid Arthritis · Rheumatoid Arthritis

#RheumatoidArthritis#Antibody#Phase3#항체#면역항체+2

임상시험 1상태 ACTIVE

AntibodystaleInstitute for Clinical and Expe…Preclinical

MabCampath, (MabCampath,)

Kidney Transplantation · Kidney Transplantation

#KidneyTransplantation#Antibody#Preclinical#항체#면역항체+2

임상시험 1상태 ACTIVE

AntibodystaleGlostrup University Hospital, C…Approved

etanercept or adalimumab (Discontinuation of TNF-alpha inhibitor and re-starting it if flare-up in disease activity, Discontinuation of TNF-alpha inhibitor and re-starting it if flare-up in disease activity (etanercept or adalimumab))

SPONDYLOARTHRITIS · SPONDYLOARTHRITIS

#SPONDYLOARTHRITIS#Antibody#Approved#항체#면역항체+2

임상시험 1상태 DISCONTINUED

AntibodystaleJanssenPreclinical

ustekinumab (Stelara, infliximab, adalimumab, golimumab, vedolizumab, ustekinumab)

Ulcerative Colitis · Ulcerative Colitis

#UlcerativeColitis#Antibody#Preclinical#항체#면역항체+2

임상시험 1상태 ACTIVE

AntibodystaleAbbViePhase 3

adalimumab (Humira, Adalimumab injections for acute disc prolapse patients)

Disc Prolapse; Pain · Disc Prolapse

#DiscProlapse#Antibody#Phase3#항체#면역항체+3

임상시험 1상태 ACTIVE

AntibodystaleAbbViePhase 1

adalimumab (Humira, adalimumab-US source)

Healthy · Healthy

#Healthy#Antibody#Phase1#항체#면역항체+2

임상시험 1상태 ACTIVE

AntibodystaleSanofiPhase 1

Dupilumab coformulated with berahyaluronidase alfa (Dupilumab coformulated with berahyaluronidase alfa)

Healthy Volunteers · Healthy Volunteers

#HealthyVolunteers#Antibody#Phase1#항체#면역항체+2

임상시험 1상태 RECRUITING

AntibodystaleSanofiPhase 2

blinded (Dupilumab, Dupilumab (blinded))

Eosinophilic Gastritis; Eosinophilic Gastroenteritis · Eosinophilic Gastritis

#EosinophilicGastritis#Antibody#Phase2#항체#면역항체+3

임상시험 1상태 ACTIVE

AntibodystaleUniversity of Illinois at Chica…Phase 3

Elra (Elranatamab, Elranatamab (Elra))

Plasmablastic Lymphoma; Hiv · Plasmablastic Lymphoma

#PlasmablasticLymphoma#Antibody#Phase3#항체#면역항체+3

임상시험 1상태 RECRUITING

AntibodystaleJanssenPhase 2

Amivantamab and Recombinant Human Hyaluronidase (Amivantamab and Recombinant Human Hyaluronidase)

Locally Recurrent Skin Squamous Cell Carcinoma; Metastatic Skin Squamous Cell Carcinoma · Locally Recurrent Skin Squamous Cell Car

#LocallyRecurrentSkinSquamousCell#Antibody#Phase2#항체#면역항체+3

임상시험 1상태 DISCONTINUED

AntibodystaleChinese PLA General HospitalPhase 2

metoprolol, infliximab, etanercept, tocilizumab and/or other agents (metoprolol, infliximab, etanercept, tocilizumab and/or other agents)

Solid Tumor; Hematological Malignancy · Solid Tumor

#SolidTumor#Antibody#Phase2#항체#면역항체+3

임상시험 1상태 ACTIVE

AntibodystaleInstitut für Klinische Krebsfor…Phase 2

Glofitamab, Gemcitabine, and Oxaliplatin as Induction Therapy (Glofitamab, Gemcitabine, and Oxaliplatin as Induction Therapy)

Relapsed /Refractory DLBCL · FRα

#FR#Antibody#Phase2#항체#면역항체+4

임상시험 1상태 RECRUITING

AntibodystaleZhejiang Cancer HospitalPhase 2

Recombinant human adenovirus type 5＋Camrelizumab (Recombinant human adenovirus type 5＋Camrelizumab)

Uterine Cervical Neoplasms; Oncolytic Virotherapy · Uterine Cervical Neoplasms

#UterineCervicalNeoplasms#Antibody#Phase2#항체#면역항체+3

임상시험 1상태 ACTIVE

105 / 165 페이지

← 이전 다음 →

전체 9,268개 프로그램 보기

갱신 기록 없음 · 14일 주기 · 방문 153 / 1,064

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

111Indium-bevacizumab (111Indium-bevacizumab)

Utidelone combined with Bevacizumab (Utidelone combined with Bevacizumab)

Bevacizumab + Pemetrexed (Bevacizumab + Pemetrexed)

Bevacizumab + Pemetrexed + Carboplatin (Bevacizumab + Pemetrexed + Carboplatin)

IBI-323 combined with bevacizumab plus Platinum (IBI-323 combined with bevacizumab plus Platinum)

PD-1 inhibitor， bevacizumab (PD-1 inhibitor， bevacizumab)

bevacizumab and Irinotecan and radiotherapy (bevacizumab and Irinotecan and radiotherapy)

sunitinib, sorafenib, bevacizumab, and pazopanib (Targeted agents indicated in management of advanced/metastatic RCC, Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib))

Faminitib or bevacizumab (Faminitib or bevacizumab)

Bevacizumab and Temozolomide and radiotherapy (Bevacizumab and Temozolomide and radiotherapy)

Gene evolution and molecular response under Bevacizumab treatment (Gene evolution and molecular response under Bevacizumab treatment)

TDM-based infliximab intravenous therapy (TDM-based infliximab intravenous therapy)

proposed biosimilar to infliximab (SB2, SB2 (proposed biosimilar to infliximab))

MabCampath, (MabCampath,)

etanercept or adalimumab (Discontinuation of TNF-alpha inhibitor and re-starting it if flare-up in disease activity, Discontinuation of TNF-alpha inhibitor and re-starting it if flare-up in disease activity (etanercept or adalimumab))

ustekinumab (Stelara, infliximab, adalimumab, golimumab, vedolizumab, ustekinumab)

adalimumab (Humira, Adalimumab injections for acute disc prolapse patients)

adalimumab (Humira, adalimumab-US source)

Dupilumab coformulated with berahyaluronidase alfa (Dupilumab coformulated with berahyaluronidase alfa)

blinded (Dupilumab, Dupilumab (blinded))

Elra (Elranatamab, Elranatamab (Elra))

Amivantamab and Recombinant Human Hyaluronidase (Amivantamab and Recombinant Human Hyaluronidase)

metoprolol, infliximab, etanercept, tocilizumab and/or other agents (metoprolol, infliximab, etanercept, tocilizumab and/or other agents)

Glofitamab, Gemcitabine, and Oxaliplatin as Induction Therapy (Glofitamab, Gemcitabine, and Oxaliplatin as Induction Therapy)

Recombinant human adenovirus type 5＋Camrelizumab (Recombinant human adenovirus type 5＋Camrelizumab)

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

실시간 이슈 · 검색

111Indium-bevacizumab (111Indium-bevacizumab)

Utidelone combined with Bevacizumab (Utidelone combined with Bevacizumab)

Bevacizumab + Pemetrexed (Bevacizumab + Pemetrexed)

Bevacizumab + Pemetrexed + Carboplatin (Bevacizumab + Pemetrexed + Carboplatin)

IBI-323 combined with bevacizumab plus Platinum (IBI-323 combined with bevacizumab plus Platinum)

PD-1 inhibitor， bevacizumab (PD-1 inhibitor， bevacizumab)

bevacizumab and Irinotecan and radiotherapy (bevacizumab and Irinotecan and radiotherapy)

sunitinib, sorafenib, bevacizumab, and pazopanib (Targeted agents indicated in management of advanced/metastatic RCC, Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib))

Faminitib or bevacizumab (Faminitib or bevacizumab)

Bevacizumab and Temozolomide and radiotherapy (Bevacizumab and Temozolomide and radiotherapy)

Gene evolution and molecular response under Bevacizumab treatment (Gene evolution and molecular response under Bevacizumab treatment)

TDM-based infliximab intravenous therapy (TDM-based infliximab intravenous therapy)

proposed biosimilar to infliximab (SB2, SB2 (proposed biosimilar to infliximab))

MabCampath, (MabCampath,)

etanercept or adalimumab (Discontinuation of TNF-alpha inhibitor and re-starting it if flare-up in disease activity, Discontinuation of TNF-alpha inhibitor and re-starting it if flare-up in disease activity (etanercept or adalimumab))

ustekinumab (Stelara, infliximab, adalimumab, golimumab, vedolizumab, ustekinumab)

adalimumab (Humira, Adalimumab injections for acute disc prolapse patients)

adalimumab (Humira, adalimumab-US source)

Dupilumab coformulated with berahyaluronidase alfa (Dupilumab coformulated with berahyaluronidase alfa)

blinded (Dupilumab, Dupilumab (blinded))

Elra (Elranatamab, Elranatamab (Elra))

Amivantamab and Recombinant Human Hyaluronidase (Amivantamab and Recombinant Human Hyaluronidase)

metoprolol, infliximab, etanercept, tocilizumab and/or other agents (metoprolol, infliximab, etanercept, tocilizumab and/or other agents)

Glofitamab, Gemcitabine, and Oxaliplatin as Induction Therapy (Glofitamab, Gemcitabine, and Oxaliplatin as Induction Therapy)

Recombinant human adenovirus type 5＋Camrelizumab (Recombinant human adenovirus type 5＋Camrelizumab)

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

실시간 이슈 · 검색

111Indium-bevacizumab (111Indium-bevacizumab)

Utidelone combined with Bevacizumab (Utidelone combined with Bevacizumab)

Bevacizumab + Pemetrexed (Bevacizumab + Pemetrexed)

Bevacizumab + Pemetrexed + Carboplatin (Bevacizumab + Pemetrexed + Carboplatin)

IBI-323 combined with bevacizumab plus Platinum (IBI-323 combined with bevacizumab plus Platinum)

PD-1 inhibitor， bevacizumab (PD-1 inhibitor， bevacizumab)

bevacizumab and Irinotecan and radiotherapy (bevacizumab and Irinotecan and radiotherapy)

sunitinib, sorafenib, bevacizumab, and pazopanib (Targeted agents indicated in management of advanced/metastatic RCC, Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib))

Faminitib or bevacizumab (Faminitib or bevacizumab)

Bevacizumab and Temozolomide and radiotherapy (Bevacizumab and Temozolomide and radiotherapy)

Gene evolution and molecular response under Bevacizumab treatment (Gene evolution and molecular response under Bevacizumab treatment)

TDM-based infliximab intravenous therapy (TDM-based infliximab intravenous therapy)

proposed biosimilar to infliximab (SB2, SB2 (proposed biosimilar to infliximab))

MabCampath, (MabCampath,)

etanercept or adalimumab (Discontinuation of TNF-alpha inhibitor and re-starting it if flare-up in disease activity, Discontinuation of TNF-alpha inhibitor and re-starting it if flare-up in disease activity (etanercept or adalimumab))

ustekinumab (Stelara, infliximab, adalimumab, golimumab, vedolizumab, ustekinumab)